Skip to main content

Advertisement

Table 1 (abstract P197). See text for description

From: Proceedings of the 25th European Paediatric Rheumatology Congress (PReS 2018)

  JIA (N=121) p
MTXO: MTXSC, n 45 : 76  
MTX dose, median (IQR) mg/m2/week 9.7 (9.0 – 10.9) -
 MTXo : MTXSC 9.6 (9.0-10.7) : 9.8 (8.8-11.1) 0.86
MTX treatment duration, median (IQR) days 340 (142-766) -
 MTXo : MTXSC 261 (143-543) : 417 (134-853) 0.39
BAI-Y raw score (total 0 – 60), mean (95%CI) 27.4 (26.2 – 28.6) -
 MTXintol : MTXtol(MISS) 27.8 (26.1-29.4) :26.9 (25.3-28.6) 0.48
 MTX-induced nausea: All others (Diary) 28.0 (26.3-29.6) : 24.4 (22.8-26.0) 0.0024
Unfavourable Coping Strategies[1], mean (95% CI) 16.5 (15.5-17.5) -
 MTXintol : MTXtol (MISS) 17.3 (15.9-18.7) :15.2 (13.8-16.5) 0.0287
 MTX-induced nausea: All others (Diary) 17.7 (16.2-19.3) :13.0 (11.6-14.4) <0.0001